成人脑肿瘤体内小鼠模型:探索肿瘤发生与推进免疫治疗开发
综述总结成人脑肿瘤的基因工程小鼠模型(GEMMs)与同源移植模型,重点介绍模型来源、遗传改变背景、致癌机制及免疫相关特征;指出免疫治疗研究需免疫健全小鼠模型,本文可帮助研究者选择合适模型。
要点
- 脑肿瘤尤其胶质母细胞瘤(GBM)5年生存率仅6.6%,治疗困难。
- GEMMs携带临床相关遗传改变,广泛用于研究肿瘤起源。
- 同源移植模型潜伏期短且一致,近年免疫治疗研究需求推动其应用。
核心结论
- 本文全面总结了成人脑肿瘤的GEMMs和同源小鼠模型,强调模型来源、遗传改变背景、致癌机制和免疫相关特征等关键特征。
- 本综述可作为脑肿瘤研究界的宝贵资源,帮助选择合适模型研究癌症免疫学。
研究设计与样本
- 综述类:总结成人脑肿瘤的基因工程小鼠模型(GEMMs)和同源小鼠模型。
主要发现
- 脑肿瘤尤其胶质母细胞瘤(GBM)5年生存率仅6.6%。
- 大规模基因组研究促进了驱动人类脑肿瘤发生和进展的遗传改变的识别。
- 携带临床相关遗传改变的GEMMs广泛用于研究肿瘤起源。
- 利用GEMMs或其他来源细胞系的同源移植模型因潜伏期一致且相对较短而受欢迎。
- 近年来免疫治疗在特定癌症类型中的成功导致癌症免疫学研究激增,特别需要使用免疫健全小鼠模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain tumors, particularly glioblastoma (GBM), are devastating and challenging to treat, with a low 5-year survival rate of only 6.6%. Mouse models are established to understand tumorigenesis and develop new therapeutic strategies. Large-scale genomic studies have facilitated the identification of genetic alterations driving human brain tumor development and progression. Genetically engineered mouse models (GEMMs) with clinically relevant genetic alterations are widely used to investigate tumor origin. Additionally, syngeneic implantation models, utilizing cell lines derived from GEMMs or other sources, are popular for their consistent and relatively short latency period, addressing various brain cancer research questions. In recent years, the success of immunotherapy in specific cancer types has led to a surge in cancer immunology-related research which specifically necessitates the utilization of immunocompetent mouse models. In this review, we provide a comprehensive summary of GEMMs and syngeneic mouse models for adult brain tumors, emphasizing key features such as model origin, genetic alteration background, oncogenic mechanisms, and immune-related characteristics. Our review serves as a valuable resource for the brain tumor research community, aiding in the selection of appropriate models to study cancer immunology.
引用
- Figg J, Chen D, Falceto Font L, et al. In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development. Neuro Oncol. 2024. PMID: 38990913. doi:10.1093/neuonc/noae131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。